Free Access
Issue
Med Sci (Paris)
Volume 36, Décembre 2020
Les Cahiers de Myologie
Page(s) 17 - 21
Section Dystrophies musculaires des ceintures (LGMD)
DOI https://doi.org/10.1051/medsci/2020244
Published online 11 January 2021
  1. Richard I, Broux O, Allamand V, et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995 ; 81 : 27–40. [CrossRef] [PubMed] [Google Scholar]
  2. Duguez S, Bartoli M, Richard I. Calpain 3: a key regulator of the sarcomere?. FEBS J 2006 ; 273 : 3427–3436. [CrossRef] [PubMed] [Google Scholar]
  3. Kinbara K, Sorimachi H, Ishiura S. Suzuki K Muscle-specific calpain, p94, interacts with the extreme C-terminal region of connectin, a unique region flanked by two immunoglobulin C2 motifs. Arch Biochem Biophys 1997 ; 342 : 99–107. [CrossRef] [PubMed] [Google Scholar]
  4. Sorimachi H, Kinbara K, Kimura S, et al. Muscle-specific calpain, p94, responsible for limb girdle muscular dystrophy type 2A, associates with connectin through IS2, a p94-specific sequence. J Biol Chem 1995 ; 270 : 31158–31162. [CrossRef] [PubMed] [Google Scholar]
  5. Fardeau M, Hillaire D, Mignard C, et al. Juvenile limb-girdle muscular dystrophy. Clinical, histopathological and genetic data from a small community living in the Reunion Island. Brain 1996 ; 119 : 295–308. [CrossRef] [PubMed] [Google Scholar]
  6. Bushby KM. Diagnostic criteria for the limb-girdle muscular dystrophies: report of the ENMC consortium on limb-girdle dystrophies. Neuromuscul Disord 1995 ; 5 : 71–74. [CrossRef] [PubMed] [Google Scholar]
  7. Straub V, Murphy A, Udd B, group Lws. 229th ENMC international workshop: limb girdle muscular dystrophies. Nomenclature and reformed classification Naarden, the Netherlands, 17–19 March 2017. Neuromuscul Disord 2018; 28 : 702–10. [CrossRef] [PubMed] [Google Scholar]
  8. Vissing J, Barresi R, Witting N, et al. A heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy. Brain 2016 ; 139 : 2154–2163. [CrossRef] [PubMed] [Google Scholar]
  9. Nallamilli BRR, Chakravorty S, Kesari A, et al. Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients. Ann Clin Trans Neurol 2018 ; 5 : 1574–1587. [CrossRef] [Google Scholar]
  10. Gonzalez-Mera L, Ravenscroft G, Cabrera-Serrano M, et al. Heterozygous CAPN3 missense variants causing autosomal-dominant calpainopathy in seven unrelated families. Neuropathol Appl Neurobiol 2020; Sep 8. doi: 10.1111/nan.12663. [Google Scholar]
  11. Vissing J, Dahlqvist JR, Roudaut C, et al. A single c.1715G>C calpain 3 gene variant causes dominant calpainopathy with loss of calpain 3 expression and activity. Hum Mutat 2020; 41 : 1507–13. [PubMed] [Google Scholar]
  12. Cerino M, Campana-Salort E, Salvi A, et al. Novel CAPN3 variant associated with an autosomal dominant calpainopathy. Neuropathol Appl Neurobiol 2020; 46 : 564–78. [CrossRef] [PubMed] [Google Scholar]
  13. Lostal W, Urtizberea JA, Richard I. 233rd ENMC International workshop: clinical trial readiness for calpainopathies, Naarden, The Netherlands, 15–17 September 2017. Neuromuscul Disord 2018 ; 28 : 540–549. [CrossRef] [PubMed] [Google Scholar]
  14. Richard I, Hogrel JY, Stockholm D, et al. Natural history of LGMD2A for delineating outcome measures in clinical trials. Ann Clin Trans Neurol 2016 ; 3 : 248–265. [CrossRef] [Google Scholar]
  15. Keira Y, Noguchi S, Kurokawa R, et al. Characterization of lobulated fibers in limb girdle muscular dystrophy type 2A by gene expression profiling. Neurosci Res 2007 ; 57 : 513–521. [CrossRef] [PubMed] [Google Scholar]
  16. Milic A, Daniele N, Lochmuller H, et al. A third of LGMD2A biopsies have normal calpain 3 proteolytic activity as determined by an in vitro assay. Neuromuscul Disord 2007 ; 17 : 148–156. [CrossRef] [PubMed] [Google Scholar]
  17. Barp A, Laforet P, Bello L, et al. European muscle MRI study in limb girdle muscular dystrophy type R1/2A (LGMDR1/LGMD2A). J Neurol 2020; 267 : 45–56. [Google Scholar]
  18. Bartoli M, Roudaut C, Martin S, et al. Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A. Mol Ther 2006 ; 13 : 250–259. [CrossRef] [PubMed] [Google Scholar]
  19. Roudaut C, Le Roy F, Suel L, et al. Restriction of calpain3 expression to the skeletal muscle prevents cardiac toxicity and corrects pathology in a murine model of limb-girdle muscular dystrophy. Circulation 2013 ; 128 : 1094–1104. [CrossRef] [PubMed] [Google Scholar]
  20. Lostal W, Roudaut C, Faivre M, et al. Titin splicing regulates cardiotoxicity associated with calpain 3 gene therapy for limb-girdle muscular dystrophy type 2A. Sci Trans Med 2019; 11 (520). [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.